PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Go online to PeerView.com/GFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in influenza discusses the use of antiviral therapy in pediatric patients with influenza. Upon completion of this activity, participants will be able to: Discuss the underutilization of antiviral treatment for both adult and pediatric patients in the management of influenza, despite recommendations from practice guidelines, Describe the benefits and shortcomings associated with the use of diagnostic assays in detecting influenza in terms of sensitivity, specificity, and convenience, Assess currently available and novel/emerging antiviral therapies for the treatment of pediatric patients with influenza, based on the latest clinical data concerning efficacy, safety, tolerability, dosing, and routes of administration, Select antiviral treatment for pediatric patients with influenza, based on the latest clinical evidence and current guideline recommendations.

Go online to PeerView.com/EMM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry, neurology, and movement disorders discusses the recognition and management of tardive dyskinesia. Upon completion of this activity, participants should be better able to: Recognize the underlying pathophysiology of tardive dyskinesia, typical symptoms, and the burden on patient quality of life, Apply evidence-based criteria to differentially diagnose tardive dyskinesia from other hyperkinetic movement disorders, Employ the latest clinical evidence on efficacy and safety regarding the use of VMAT2 inhibitors to the management of patients with tardive dyskinesia.

Go online to PeerView.com/BQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer. In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants will be able to: Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1), Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors, Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors), Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients, Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care.

Go online to PeerView.com/JBC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immunotherapy has become a new pillar in the treatment arsenal for advanced triple-negative breast cancer (TNBC), and accumulating evidence is supporting its expansion into earlier disease stages as well. To make the most of this therapeutic approach as a component of multimodal management of patients, especially in curative intent settings, it is increasingly important for breast surgeons, medical oncologists, radiation oncologists, pathologists, and other healthcare professionals to collaborate and coordinate the care of patients with TNBC. This educational on-demand activity based on a recent live web broadcast provides up-to-date information and multidisciplinary perspectives on the current and emerging roles of immune checkpoint inhibitors and combinations throughout the disease continuum of TNBC, as well as practical guidance for optimal integration of these therapies into clinical practice, focusing on the most important implications for breast surgeons. Upon completion of this activity, participants will be able to: Discuss the biologic rationale and rational strategies for harnessing the immune system in the treatment of triple-negative breast cancer (TNBC), including combinatorial or sequential approaches with immune checkpoint inhibitors and other effective therapies that may enhance immunogenicity and improve outcomes, Assess the efficacy, safety, biomarker, and other key data from clinical trials assessing immunotherapy and immune-based combinations or sequential strategies with other effective treatment modalities throughout the continuum of TNBC, including early-stage (neoadjuvant/adjuvant settings) and advanced/metastatic disease, Incorporate immunotherapies into treatment plans for patients with TNBC based on the latest evidence, indications, recommendations, disease stage/treatment setting, patient and tumor characteristics, and other relevant factors in the context of effective multidisciplinary collaboration.

Go online to PeerView.com/YHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this CME video activity, experts in systemic lupus erythematosus (SLE) give a detailed discussion on the autoimmune disease, providing guidance on recognizing the clinical features and confirming a diagnosis, as well as contemporary strategies to manage diverse disease manifestations. Hear what the experts are doing in their clinics. Upon completion of this activity, participants should be better able to: Identify systemic lupus erythematosus (SLE) as a heterogeneous autoimmune disease with a wide range of clinical and serological manifestations that can affect any organ, Employ appropriate criteria to confirm a diagnosis of SLE, recognizing the clinical utility of available classification systems, Utilize evidence-based tools to monitor disease activity in individual SLE patients in daily clinical practice and guide treatment decisions, Describe current treatment options for SLE according to mechanism of action, efficacy, safety, and impact on patient symptoms/quality of life, Develop treatment plans for individual patients with SLE to control disease activity and prevent or minimize disease flares, drug toxicity, and organ damage, Effectively communicate and collaborate with SLE patients and other care providers to understand and address the needs of each patient and maximize treatment adherence, quality of life, and survival outcomes.

Go online to PeerView.com/QTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in obesity management discusses aspects of obesity management, including current recommendations, the role of weight-loss pharmacotherapies, evidence regarding current and emerging weight-loss pharmacotherapies, and patient-centered treatment approaches. Upon completion of this activity, participants should be better able to: Summarize current treatment recommendations, with rationale for the long-term use of weight-loss pharmacotherapy in the management of obesity as a chronic disease, Evaluate recent evidence regarding available and emerging weight-loss agents, including current data on efficacy, safety, and anticipated effects in the context of obesity pathophysiology, Incorporate weight-loss pharmacotherapy in personalized obesity management plans, based on disease status and patient characteristics and preferences, Use motivational techniques to engage and support individuals in obesity management.

Go online to PeerView.com/HNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses SMA presentation and progression, the importance of early SMA diagnosis, treatments approved for SMA, recommendations for symptomatic care, and methods for supporting patients with SMA and their caregivers. Upon completion of this activity, participants should be better able to: Recognize the role of newborn screening in overcoming diagnostic delays in spinal muscular atrophy, Apply current data on the efficacy, safety, and tolerability of approved therapies for the treatment of spinal muscular atrophy from infancy through adulthood, Identify how symptomatic monitoring and support may evolve in patients with spinal muscular atrophy over the course of their disease, Employ symptomatic care in conjunction with approved treatments to optimize outcomes in patients with spinal muscular atrophy.

Go online to PeerView.com/VRT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts provides unique perspectives on applying an evidence-based, patient-centered approach to psoriatic disease care. Upon completion of this activity, participants will be able to: Describe the pathophysiology and clinical presentations of psoriasis and psoriatic arthritis (PsA), Employ strategies to screen patients for comorbidities associated with psoriatic disease, Discuss current and emerging treatment options for psoriatic disease in the context of mechanism of action, efficacy, safety, and optimal clinical use, Design individualized treatment plans for patients with psoriatic disease based on evidence-based guidelines, safety and efficacy of pharmacologic treatment options, disease severity, and patient quality of life (QoL) factors.

Go online to PeerView.com/NDJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a stroke and vascular neurologist shares a patient case to provide clinical relevance and a practical exploration of the latest advances in the diagnosis and treatment of patients with a large hemispheric infarction (LHI). Upon completion of this activity, participants should be better able to: Apply current evidence-based guidelines to diagnose and treat patients with an LHI, Identify clinical characteristics associated with increased risk of cerebral edema in patients following an LHI, Summarize the benefits and limitations of current and emerging therapeutic strategies to prevent cerebral edema in patients following an LHI.

Go online to PeerView.com/WXC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses practical strategies for identifying and managing axial spondyloarthritis (axSpA) in clinical practice. Upon completion of this activity, participants should be better able to: Identify axSpA in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Apply classification criteria and diagnostic tests into clinical practice to support early detection of axSpA, Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences, Recognize the importance of collaborating with rheumatologists to provide optimal treatment and longitudinal support for patients with axSpA.